Selecting treatment options in refractory metastatic colorectal cancer

OncoTargets and Therapy

关键词: TKI;    fluoropyrimidine;    bevacizumab;    cetuximab;    panitumumab;    PD-1 inhibitor;    FOLFIRI;    epidermal growth factor receptor;    vascular endothelial growth factor receptor;    platelet-derived growth factor receptors;    KRAS;    NRAS;    HER2;    advanced;    colon cancer;    refractory;    lonsurf;    regorafenib;   

DOI  :  

来源: DOAJ

【 摘 要 】

Margaret Byrne, Muhammad Wasif SaifNorthwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra, Lake Success, NY, USAAbstract: Survival of patients with metastatic colorectal cancer (mCRC) has significantly improved in the last decade. Survival gains are not driven by advances in first-line therapy but by incremental additional effects of subsequent treatment lines. To maximize outcomes, patients should receive all active agents. Identification of patient subgroups is increasing individualization of treatment. Novel oral agents, such as regorafenib and TAS-102, as well as promising immunotherapeutic agents have offered salvage treatment options for refractory mCRC. Although most therapeutic developments for mCRC in the chemorefractory setting focuses on new targets and/or more potent agents, reconsideration of established targets has gained importance with the growth of a rational pharmacogenomic approach to drug development, such as HER2. The authors describe treatment options for patients with refractory colon cancer following first- and second-line therapy.Keywords: TKI, fluoropyrimidine, bevacizumab, cetuximab, panitumumab, PD-1 inhibitor, FOLFIRI, epidermal growth factor receptor, vascular endothelial growth factor receptor, platelet-derived growth factor receptors, KRAS, NRAS, HER2, advanced, colon cancer, refractory, Lonsurf, regorafenib

【 授权许可】

Unknown